Evidence map›Paper›PMID 24357868›Full record

ReviewThe Canadian journal of hospital pharmacy2013

Treatment Strategies for Recurrent Clostridium difficile Infection.

Christine Leong, Sheryl Zelenitsky

Open access · bronzeAbstract readReview
In one paragraph

Review in The Canadian journal of hospital pharmacy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Comprehensive Evaluation of the Efficacy and Safety of theThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Article
  7. Therapeutics involved in managing initial and recurrentWorld journal of gastrointestinal pharmacology and therapeutics · 2024
    Review
  8. Review
  9. Microbiota-Based Live Biotherapeutic Products forInfection and drug resistance · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. The role of the gut microbiome in colonization resistance and recurrentTherapeutic advances in gastroenterology · 2022
    Review
  17. Health care resource utilization and costs of recurrentJournal of managed care & specialty pharmacy · 2021
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Christine Leong, BScPhm, PharmD, is with the Faculty of Pharmacy, Apotex Centre, University of Manitoba, Winnipeg, Manitoba.
Sheryl Zelenitsky, BScPhm, PharmD, is with the Faculty of Pharmacy, Apotex Centre, University of Manitoba, Winnipeg, Manitoba.
University of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecurrent Clostridium difficile infection represents a major clinical challenge. Treatment is often based on empiric selection from relatively few options supported by limited clinical evidence.

objectiveTo review and evaluate the literature on therapeutic alternatives for recurrent C. difficile infection. DATA SOURCES: The MEDLINE, PubMed, Embase, and Cochrane databases were searched from inception to 2013 for published evidence in English on the treatment of recurrent C. difficile infection. The search terms were "Clostridium difficile", "recurrent" or "relapse", and "treatment". STUDY SELECTION AND DATA EXTRACTION: Studies of any design were eligible for inclusion. Two reviewers assessed abstracts, full articles, and reference lists from retrieved articles and clinical practice guidelines to identify relevant literature. DATA SYNTHESIS: The evidence to guide treatment of recurrent C. difficile infection is limited, with 24 studies meeting the inclusion criteria for this review. A repeat course of oral metronidazole or vancomycin is recommended for treatment of mild to moderate first recurrences and has not been found to influence the likelihood of subsequent recurrence. Oral vancomycin may be preferred for more severe infections; however, the severity score warrants further study and validation. For the treatment of second and subsequent recurrences, tapered or pulsed vancomycin regimens have been recommended in practice guidelines, despite very limited clinical evidence. Similarly, the potential benefits of longer treatment courses of oral vancomycin for second and subsequent recurrences warrant investigation. The potential role, including costs and benefits, of new agents such as fidaxomicin in the treatment of recurrent C. difficile infection remains to be determined. Although there is insufficient evidence to recommend probiotics as an adjunct to conventional treatment for recurrent infection, there may be benefit in terms of prevention.

conclusionsThis literature review identified significant limitations in currently recommended interventions for the treatment of recurrent C. difficile infection. It has also provided insight into the available evidence for determining the appropriateness of therapy for patients with recurrent infection.

Indexed as

fidaxomicinliterature reviewmetronidazolerecurrent Clostridium difficile infectionrelapsevancomycin

Identifiers

PMID24357868
PMCPMC3867563
OpenAlexW2076426711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.